View Schedule

34^th Annual Meeting & Pre-Conference Programs Schedule
Wednesday, Nov. 6, 2019
World Immunotherapy Council’s 3rd Young Investigator Symposium
Time: Location:	7:30 a.m. – 1:00 p.m. Cherry Blossom Ballroom
Adoptive T Cell Therapies
7:30 a.m.	Longitudinal Tracking of WT1-specific T-cells Allows to Generate a Library of WT1-specific TCRs, for TCR Gene Editing of Acute Leukemia Eliana Ruggiero, PhD – San Raffaele Scientific Institute (ATTACK)
7:45 a.m.	Arming T cells with Chemokine Receptors Enables Adoptive T cell Therapy of Cancer Sebastian Kobold, MD – Klinikum der Universität München (CDDF)
8:00 a.m.	Targeting CD20 – A Functional Comparison of TCR and CAR Transduced T cells Tassilo Wachsmann, MSc – Leiden University Medical Center (DTIM)
8:15 a.m.	Genetic Manipulation of Antitumor T cells to Elicit a Durable Clinical Response in Adoptive Immunotherapy Yuki Kagoya, MD, PhD – The University of Tokyo Hospital (JACI)
8:30 a.m.	Engineering Adoptive T cell Therapy to Overcome Immune Suppression in Ovarian Cancer Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center (SITC)
8:45 a.m.	Combination of Short-lived and Extended Half-life Target Modules for Optimized UniCAR T cell Therapy Claudia Arndt, PhD – Helmholtz-Zentrum Dresden-Rossendorf (TIMO)
Gene Profiling and Identification of Biomarkers
9:00 a.m.	Immune Monitoring for Clarifying Optimal Immunotherapy Hye Kim, MD, PhD – Division of Medical Oncology, Yonsei Cancer Center (KCA)
9:15 a.m.	Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma Haoyu Sun, PhD – University of Science and Technology of China (TIBIT)
9:30 a.m.	Gene Profile Analysis of Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors Domenico Mallardo, MD – Istituto Nazionale Tumori - IRCCS - "Fondazione G.Pascale" (SCITO)
9:45 a.m.	Genomic Instability, Tumor Mutation Burden and Biomarkers in Lung Cancer and Other Solid Tumors Kai He, MD, PhD – Ohio State University James Cancer Hospital (CAHON)
10:00 a.m.	NY-ESO-1- and Melan-A-reactive T-cells Disappear from the Circulation in Clinical Responders to PD-1 Blockade in Melanoma Kilian Wistuba-Hamprecht, Dr. rer. nat – Department of Dermatology, University Hospital Tübingen (PIVAC)
10:15 a.m.	Break
Immune Checkpoint Inhibitors
10:30 a.m.	Low Molecular Weight Heparin Augments the Effectiveness of Immune Checkpoint Inhibitors in Vitro and in Vivo Panagiotis Sarantis, MSc – Medical School of Athens (University of Athens)
10:45 a.m.	The Clinical Utility and Safety of Immune Check Point Inhibitors (ICI) - Multicentric Data from India George Abraham, MD – Tata Memorial Centre (I-OSI)
11:00 a.m.	Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade Davis Torrejon, MD – UCLA Hematology-Oncology (GETICA)
11:15 a.m.	Novel Immunotherapies and Regional Chemotherapy in Uveal Melanoma Gitta Panczel, MD – National Institute of Oncology (National Institute of Oncology, Budapest)
11:30 a.m.	Rational Combination of a Small Inhibitor and Immune Checkpoint Blockade in Hepatocellular Carcinoma Preclinical Models Timothy Shuen, PhD – National Cancer Centre Singapore (SSO-CIC)
Novel Treatments
11:45 a.m.	Reprogramming CD8 Cells into Metabolically Fit Stem Cell Memory with Superior Therapeutic Activity by MEK1/2 Manipulation Vivek Verma, PhD – Georgetown Lombardi Comprehensive Cancer Center (TVACT)
12:00 p.m.	Podocalyxin is a Therapeutic Target in Carcinoma Diana Canals Hernaez, BSc – The University of British Columbia (CCIC)
12:15 p.m.	Manipulation of Lipid Metabolism in Monocyte-derived DC Enhance Their Interaction with Natural Killer Cells Chiara Massa, PhD – Martin Luther University Halle-Wittenberg (GIS)
12:30 p.m.	The Role of Phytocannabinoids in Cancer Nadine Hall, BSc – St. George's, University of London (ICVI)
12:45 p.m.	Antibody Targeting of Tumor Associated Macrophages in Pancreatic Cancer and Melanoma Remodel the Tumor Microenvironment and Revives Immune Targeting of Tumor Cell Dhifaf Sarhan, PhD – Karolinska Institutet (SNIC)
Novel Multi-Targeted Therapeutic Platforms
Time: Location:	2:00 - 6:30 p.m. Cherry Blossom Ballroom
Session 1: Basics of Multi-Targeted Therapeutic Platforms
2:00 p.m.	Introduction
2:05 p.m.	Overview of Different Platform Structures
2:25 p.m.	Cytokine Fusions Raphael Clynes, MD, PhD – Xencor, Inc.
2:45 p.m.	Multi-Targeted CAR T cells Marcela V. Maus, MD, PhD – Massachusetts General Hospital
3:05 p.m.	BiTEs, TriKEs, TriNKETs Jeffrey S. Miller, MD -- University of Minnesota
3:25 p.m.	Break
3:40 p.m.	Pros and Cons of Multi-Targeted Therapeutics Panel Discussion Panelists: Raphael Clynes, MD, PhD – Xencor, Inc. David S. Hong, MD – The University of Texas MD Anderson Cancer Center Israel Lowy, MD, PhD – Regeneron Pharmaceuticals Marcela V. Maus, MD, PhD – Massachusetts General Hospital Jeffrey S. Miller, MD -- University of Minnesota
Session 2: Novel Platforms and Innovation
4:15 p.m	Contextual reprogramming of T cells for multi-targeted therapeutics: checkpoint blockade, immune resilience, and stemness to overcome immune resistance and reduce toxicity, all in one cell product Francesco M. Marincola, MD – Refuge Biotechnologies
4:25 p.m.	The first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog IMA101-101) Steffen Walter, PhD – Immatics US
4:35 p.m.	A novel fully synthetic dual targeted Nectin-4/4-1BB Bicycle® peptide induces tumor localized 4-1BB agonism Nicholas Keen, PhD – Bicycle Therapeutics
4:45 p.m.	Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies Tibor Keler, PhD – Celldex Therapetuics, Inc.
4:55 p.m.	Development of novel multi-specific compounds for cancer immunotherapy using the DARPin® technology platform Victor Levitsky, MD, PhD – Molecular Partners AG
5:05 p.m.	The uniqueness and persistence of clonal profiles associated with response in study C-144-01 following treatment with lifileucel (LN-144) supports using a polyclonal product to treat solid tumors Viktoria Gontcharova, PhD – Iovance Biotherapeutics
5:15 p.m.	Break
Session 3: Clinical Applications of Multi-Targeted Therapeutic Platforms
5:30 p.m.	Clinical Trial Designs R. Angelo De Claro, MD – Food and Drug Administration
5:50 p.m.	Compare and Contrast with Cellular Therapies Panel Discussion Panelists: R. Angelo De Claro, MD – Food and Drug Administration Steffen Walter, PhD – Immatics US Victor Levitsky, MD, PhD – Molecular Partners AG Tibor Keler, PhD – Celldex Therapetuics, Inc. Francesco M. Marincola, MD – Refuge Biotechnologies Nicholas Keen, PhD – Bicycle Therapeutics Marcela V. Maus, MD, PhD – Massachusetts General Hospital
6:25 p.m.	Closing
Thursday, Nov. 7, 2019
Primer on Tumor Immunology and Cancer Immunotherapy™
Time: Location:	8:00 a.m. - 5:00 p.m. Potomac Ballroom AB
Primer Session 1: Tumor Immunity I
8:00 a.m.	Introduction Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
8:05 a.m.	The Adaptive Immune Response Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
8:35 a.m.	Macrophages, Dendritic and Myeloid Cells Tyler Curiel, MD – UT Health San Antonio
9:05 a.m.	Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai
9:35 a.m.	Tumor Immunity I Panel Discussion Moderator: Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center Panelists: Tyler Curiel, MD – UT Health San Antonio Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
9:55 a.m.	Break
Primer Session 2: Tumor Immunity II
10:10 a.m.	Regulation of Cancer Immunity by Metabolic and Microbiome Interactions Greg Delgoffe, PhD – University of Pittsburgh
10:40 a.m.	Redefining Cancer Vaccination Tanja de Gruijl, PhD – VU University Medical Center
11:10 a.m.	Monoclonal Antibodies and Their Derivatives Charles G. Drake, MD, PhD – Columbia University
11:40 a.m.	Tumor Immunity II Panel Discussion Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine Panelists: Tanja de Gruijl, PhD – VU University Medical Center Greg Delgoffe, PhD – University of Pittsburgh Charles G. Drake, MD, PhD – Columbia University
12:00 p.m.	Lunch
Sponsored Symposia
Time: Location:	11:30 a.m. – 1:00 p.m. Riverview Ballroom B 4-5
11:30 a.m.	Registration and Lunch
12:00 p.m.	Immunotherapy in Urothelial Bladder Cancer: Current Treatments and Emerging Research Clinical Care Options, LLC.
Primer Session 3: Analysis of Resistance and Response
1:00 p.m.	Introduction Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
1:05 p.m.	Extrinsic Mechanisms of Resistance: A Miserable Microenvironment Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
1:35 p.m.	Checkpoint Receptors - Pathways to Resistance Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2:05 p.m.	Biomarkers of Response to Immunotherapy Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
2:35 p.m.	Analysis of Resistance and Response Panel Discussion Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine Panelists: Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai
2:55 p.m.	Break
Primer Session 4: Current IO Immunotherapy
3:10 p.m.	Adoptive T Cell Therapy Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
3:40 p.m.	Combination Immunotherapies Leisha Emens, MD, PhD – University of Pittsburgh
4:10 p.m.	Diagnosis, Management and Mechanisms of Immune-related Adverse Events Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine
4:40 p.m.	Current IO Immunotherapy Panel Discussion Moderator: Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center Panelists: Leisha Emens, MD, PhD – University of Pittsburgh Patrick Hwu, MD – University of Texas MD Anderson Cancer Center Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine
4:55 p.m.	Closing
5:00 p.m.	Adjourn
Workshop on Intratumoral Immunomodulation
Time: Location:	8:00 a.m. – 5:00 p.m. Cherry Blossom Ballroom
Workshop Session 1: Introduction to Intratumoral Immunomodulation
8:00 a.m.	Introduction Adi Diab, MD – University of Texas MD Anderson Cancer Center
8:05 a.m.	Background and Introduction to Intratumoral Therapy Aurélien Marabelle, MD, PhD – Gustave Roussy
8:35 a.m.	Cold vs. Hot Tumors Razvan Cristescu, PhD - Merck
8:55 a.m.	Clinical Assessment of Intratumoral Immunomodulation Jianda Yuan, MD, PhD – Merck Research Laboratories
Workshop Session 2: Modes of Delivery
9:15 a.m.	Intratumoral Immunotherapies from an Interventional Radiology Perspective Rahul Sheth, MD – The University of Texas MD Anderson Cancer Center
9:35 a.m.	Attracting Dendritic Cells to the Tumor with Focal Radiotherapy Sandra Demaria, MD – Weill Cornell Medicine
9:55 a.m.	SBRT and Immune Activation Silvia Formenti, MD – New York-Presbyterian/Weill Cornell Medical Center
10:15 a.m.	Break
Workshop Session 3: Intratumoral Synthetic Modulators
10:40 a.m.	Hot is Not Enough: In Situ Vaccination to Turn Cold Tumors Hot, and Cross-Priming Joshua Brody, MD – Icahn School of Medicine at Mount Sinai
11:00 a.m.	TLR9 Adi Diab, MD – University of Texas MD Anderson Cancer Center
11:20 a.m	TLR7/8 Agonists in Immuno-Oncology Willem W. Overwijk, PhD – Nektar Therapeutics
11:40 a.m.	STING at a Crossroads: Untapped Potential for Innate Immunity Thomas W. Dubensky, PhD – Tempest Therapeutics
12:00 p.m.	Lunch
Workshop Session 4: Intratumoral Oncolytic Modulators
1:00 p.m.	The Role of T-VEC and Other Oncolytic Viruses in Priming the Tumor Microenvironment for Immunotherapy Howard L. Kaufman, MD, FACS – Replimune Group Inc.
1:20 p.m.	Intratumoral Oncolytic Immunotherapy: Is Lysis Really Necessary? Dmitry Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center
1:40 p.m.	Development of Multiplex Oncolytic Viruses John Bell, PhD – University of Ottawa
Workshop Session 5: Systemic Combinations
2:00 p.m.	Intratumoral Checkpoint Blockade Inhibition Craig L. Slingluff, MD – University of Virginia
2:20 p.m.	Anti-Tumor Vaccines Platforms Esteban Celis, MD, PhD – Augusta University
2:40 p.m.	Break
3:00 p.m.	CD40: A Target for Systemic Immune Modulation Michael Yellin, MD – Celldex Therapeutics, Inc.
3:20 p.m.	Modulating the Tumor Microenvironment Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
3:40 p.m.	Regulatory Implications for Drug Development Maitreyee Hazarika, MD – U.S. Food and Drug Administration
4:00 p.m.	Systemic Combinations Panel Discussion Moderators: Adi Diab, MD – University of Texas MD Anderson Cancer Center Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai Panelists: Esteban Celis, MD, PhD – Augusta University Jason Luke, MD, FACP – University of Pittsburgh Medical Center Craig L. Slingluff, MD – University of Virginia Michael Yellin, MD – Celldex Therapeutics, Inc. Jianda Yuan, MD, PhD – Merck Research Laboratories
4:55 p.m.	Closing Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
5:00 p.m.	Adjourn
Meet-the-Expert Lunch
Time: Location:	12:00 p.m. – 1:00 p.m. National Harbor 4-5
12:00 p.m.	Introduction/Welcome from ECS Committee
12:05 p.m.	Table 1: Basic-Translational Research in Immunology Ana Wu, PhD – City of Hope Table 2: Basic-Translational Research in Immunology Zihai Li, MD, PhD – The Ohio State University Table 3: Clinical-Translational Research in Immunology with Focus on Medical Students and Medical Residents Joshua Brody, MD – Icahn School of Medicine at Mount Sinai Table 4: Clinical-Translational Research in Immunology with Focus on Fellows and Early Career Clinicians David McDermott, MD – Beth Israel Deaconess Medical Center Table 5: Partnering and Collaborating with Industry Lazslo Radvanyi, PhD – Ontario Institute for Cancer Research Table 6: Gaining a Network and Leveraging Support Tullia Bruno, PhD – University of Pittsburgh Table 7: Career Path: The Big Pharma Industry Perspective Edward Cha, MD, PhD – Genentech Table 8: Career Path: The Small Biotech Industry Perspective Thomas Dubensky, PhD – Tempest Therapeutics
Annual Meeting Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies Organized in collaboration with the American Society of Hematology (ASH)
Time: Location: Co-Chairs:	1:00 – 5:00 p.m. Potomac Ballroom CD Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center John M. Timmerman, MD – University of California, Los Angeles
1:00 p.m.	Annual Meeting Welcome Sandra Demaria, MD – Weill Cornell Medicine
1:05 p.m.	Enhancing Myeloid cell Functionality in Tumor Lesions Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai
1:30 p.m.	Lessons and Challenges from the Immunotherapy of Lymphoma Stephen Ansell, MD, PhD – Mayo Clinic
1:55 p.m.	(O79) Mapping the spatial architecture of acute myeloid leukemia in the bone marrow microenvironment by multiplexed ion beam imaging Xavier Rovira-Clave, PhD – Stanford University
2:10 p.m.	(O3) Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study Sergio Rutella, MD, PhD, FRCPath – Nottingham Trent University
2:25 p.m.	(O71) AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells Victoria Smith, PhD – Amphivena Therapeutics, Inc.
2:40 p.m.	(O43) Immune profiling of the tumor microenvironment in classic Hodgkin lymphoma using high-complexity mass cytometry is feasible and reveals significant multi-compartment heterogeneity between patients El-ad David Amir, PhD – Astrolabe Diagnostics, Inc.
2:55 p.m.	Break
3:10 p.m.	Current State of the Art in CAR cell Therapy Marcela Maus, MD, PhD – Massachusetts General Hospital
3:35 p.m.	Addressing Relapse After CAR T cell Therapy for B cell Malignancies Terry Fry, MD – University of Colorado School of Medicine, Children's Hospital Colorado
4:00 p.m.	(O25) Dominant negative PD1 armored CAR T cells induce remission in relapsed or refractory non-hodgkin lymphoma (NHL) patients Victor Lu, PhD – Innovative Cellular Therapeutics
4:15 p.m.	(O7) P-BCMA-ALLO1 — a nonviral, allogeneic anti-BCMA CAR T therapy with potent antit-tumor function for the treatment of multiple myeloma Maximilian Richter, PhD – Poseida Therapeutics
4:30 p.m.	(O9) Enhancing affinity of CD22-directed CAR T cells increases activation signaling and in vivo response to CD22lo leukemia Zachary Walsh, BA – Children's Hospital Colorado
4:45 p.m.	(O61) Myeloid cell-targeted miR-146a mimic alleviates NF-κB-driven cytokine storm without interfering with CD19-specific CAR T cell activity against B cell lymphoma Marcin Kortylewski, PhD – City of Hope
Poster Symposium
Time: Location: Co-Chairs:	5:30 – 7:30 p.m. Potomac Ballroom CD Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Institute Roberta Zappasodi, PhD - Memorial Sloan Kettering Institute
5:30 p.m.	(O54) Germline genetic variation affects the immune response in cancer Rosalyn Sayaman, PhD – City of Hope Comprehensive Cancer Center
5:40 p.m.	(O52) ADT-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer Progression Zoila Lopez Bujanda, MS – Columbia University
5:50 p.m.	(O76) Interferon-Gamma mediated T cell exhaustion generates distinct tumor microenvironments in synchronous melanoma via PD-1/PD-L1 axis Shuyang Qin, BS – University of Rochester School of Medicine and Dentistry
6:00 p.m.	(O60) Tumor cell-intrinsic defects in STING pathway signaling and IFN-β gene regulation Blake Flood, BS – University of Chicago
6:10 p.m.	(O39) Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer Sofia Bruni, MS – Instituto de Biologia y Medicina Experimental - CONICET
6:20 p.m.	Question & Answer
6:30 p.m.	(O38) A single-dose immunotherapy that remodels the tumor microenvironment for subsequent curative responses to checkpoint blockade Chensu Wang, PhD – Massachusetts Institute of Technology
6:40 p.m.	(O37) PD1 blockade augments adoptive T cell therapy via endogenous T cells rather than direct enhancement of transferred T cells John Davies, PhD – National Institutes of Health, National Cancer Institute
6:50 p.m.	(O72) Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers Fan Zhang, PhD – Fred Hutchinson Cancer Research Center
7:00 p.m.	(O14) Immune selection for IFN-g signaling mutant cancer cells involves tumor heterogeneity and clonal cooperation Shuyin Li, PhD – University of Chicago
7:10 p.m.	(O58) Human tumor-infiltrating MAIT cells display hallmarks of antigen-recognition that are associated with tumor bacterial infiltration Shamin Li, PhD – Fred Hutchinson Cancer Research Center
7:20 p.m.	Question & Answer
Grant Writing Workshop
Time: Location:	6:00 – 8:00 p.m. National Harbor 10-11
Session I: Overview of Grant Writing
6:00 p.m.	Welcome Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine
6:05 p.m.	Overview of Grant Opportunities Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
6:15 p.m.	Principles of Grant Writing Thomas Gajewski, MD, PhD – University of Chicago
6:35 p.m.	Panel Discussion Moderator: Saman Maleki, PhD – Western University Panelists: Thomas Gajewski, MD, PhD – University of Chicago Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Session II: You Submitted Your Grant: Now What Happens?
6:45 p.m.	Attendee Review of Specific Aims Document
6:50 p.m.	A Look Inside a Study Section Denise R. Shaw, PhD – National Institutes of Health
6:55 p.m.	Mock Study Session Moderator: David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center Panelists: Ana Anderson, PhD – Harvard Medical School – Secondary Reviewer Thomas Gajewski, MD, PhD – University of Chicago – Chair Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute – Primary Reviewer Marco Ruella, MD – University of Pennsylvania – Reader Denise R. Shaw, PhD – National Institutes of Health – Scientific Review Officer Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine – Third Reviewer
7:10 p.m.	Attendee Review of Summary Statement Document
7:15 p.m.	What Happens After Reviews are Conducted/How to Revise Your Grant Malgorzata Klauzinska, PhD – National Institutes of Health
7:30 p.m.	Panel Discussion Moderator: David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center Panelists: Ana Anderson, PhD – Harvard Medical School Thomas Gajewski, MD, PhD – University of Chicago Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute Marco Ruella, MD – University of Pennsylvania Denise R. Shaw, PhD – National Institutes of Health Claire I. Vanpouille-Box, PhD – Weill Cornell Medicine
7:55 p.m.	Closing Remarks Saman Maleki, PhD – Western University

Friday, Nov. 8, 2019 Presidential Breakfast & Membership Business Meeting Time: 7:00 – 7:45 a.m. Location: Cherry Blossom Ballroom Session 200: National Cancer Institute Update
Time: Location:	7:55 – 8:35 a.m. Potomac Ballroom
7:55 a.m.	2017 NCI Immunotherapy Fellowship Ariel E. Marciscano, MD – Memorial Sloan Kettering Cancer Center
8:00 a.m.	2018 NCI Immunotherapy Fellowship Jason M. Redman, MD – National Cancer Institute
8:05 a.m.	Cancer Immunotherapy Trials Network Update Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center
8:20 a.m.	Immuno-Oncology Translational Network Update Kevin Howcroft, PhD – National Cancer Institute
Session 201: Richard V. Smalley, MD Memorial Lectureship
Time: Location: Chair:	8:35 – 9:25 a.m. Potomac Ballroom Mario Sznol, MD – Yale School of Medicine
8:35 a.m.	Introduction Mario Sznol, MD – Yale School of Medicine
8:40 a.m.	Traveling the Cancer Vaccine Road and Reaching My Destination Olivera J. Finn, PhD – University of Pittsburgh School of Medicine
9:20 a.m.	Question & Answer Olivera J. Finn, PhD – University of Pittsburgh School of Medicine
Session 202: Autoimmunity, Toxicity, and Cancer Immunotherapy
Time: Location: Co-Chairs:	9:25 a.m. – 12:00 p.m. Potomac Ballroom Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center Virginia Pascual, MD – Weill Cornell Medicine
9:25 a.m.	Introduction Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center
9:30 a.m.	Clinical Management and Research of Immune-Related Adverse Events Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center
9:50 a.m.	Basic Mechanisms in Autoimmunity/ Novel, New Data on T cells Virginia Pascual, MD – Weill Cornell Medicine
10:10 a.m.	Checkpoint Blockade and Immune Homeostasis in the Gastrointestinal Tract Michael L. Dougan, MD, PhD – Massachusetts General Hospital
10:30 a.m.	Break
10:50 a.m.	(O63) Gastric toxicity associated with PD-1 blockade therapy revealed by Multiplexed Ion Beam Imaging Selena Ferrian, PhD – Stanford University
11:05 a.m.	(O4) Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology Courtney M. Anderson, PhD – Advanced Cell Diagnostics, Inc.
11:20 p.m.	(O11) Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade Shuming Chen, PhD – Johns Hopkins University School of Medicine
11:35 a.m.	Panel Discussion Moderators: Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center Virginia Pascual, MD – Weill Cornell Medicine Panelists: Michael L. Dougan, MD, PhD – Massachusetts General Hospital
Session 203: Late-Breaking Abstract Session
Time: Location: Chair:	12:00 p.m. – 12:30 p.m. Potomac Ballroom Ana Carrizosa Anderson, PhD – Harvard Medical School
12:00 p.m.	(O83) Phase 1 study of an anti-CD27 agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors Ronnie Shapira-Frommer, MD – Oncology Institute, Sheba Medical Center, Ramat-Gan, Israel
12:15 p.m.	(O85) Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a Toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab John M. Kirkwood, MD – University of Pittsburgh Medical Center
Lunch, Exhibits and Poster Viewing
Time: Location:	12:30 – 2:00 p.m. Prince George's Exhibition Halls AB Odd Numbered Posters Presented
Sponsored Symposia
Time: Location:	12:15 – 1:45 p.m. Riverview Ballroom A3
12:15 p.m.	Registration and Lunch
12:45 p.m.	Increasing Survival in Stage III NSCLC: Optimizing Care and Addressing New Clinical Challenges Clinical Care Options, LLC.
Time: Location:	12:30 – 1:45 p.m. Riverview Ballroom B 4-5
12:30 p.m.	Registration and Lunch
12:45 p.m.	Role of Immunotherapy in Endometrial and Cervical Cancers Medscape
Concurrent Rapid Oral Abstract Presentations - Basic Research
Time: Location: Co-Chairs:	12:45 – 1:45 p.m. National Harbor 10-11 Ravi Patel, MD, PhD – University of Wisconsin-Madison Yared Hailemichael, PhD – The University of Texas MD Anderson Cancer Center
1:45 p.m.	(O62)Targeting myeloid tumors by Off-the-Shelf NK cells using an NKG2C-IL15-CD33 Trispecific Killer Engager Emily Chiu, BA – University of Minnesota
12:53 p.m.	(O59) CD8 T-cell infiltration into renal tumors requires a supportive antigen presenting niche and is independent of PD-L1 status Caroline S. Jansen, BS – Emory University
1:01 p.m.	(O53) Altered T-cell clonotype composition is strongly associated with differential functional orientation of colon cancer microenvironment Jessica Roelands – Sidra Medical Research Center
1:09 p.m.	Question & Answer Emily Chiu, BA – University of Minnesota Caroline S. Jensen, BS – Emory University Jessica Roelands – Sidra Medical Research Center
1:15 p.m.	Inhibition of autophagy enhances multifunctional genetically-engineered NK cell-based immunotherapy of glioblastoma Jiao Wang, PhD – Purdue University
1:23 p.m.	(O55) Antigen-cross presentation promotes the development of terminally differentiated CD8 T cells in young individuals Ardiana Moustaki, PhD – St. Jude Children's Research Hospital
1:31 p.m.	(O15) Replication stress response defects predict response to immune checkpoint blockade across multiple cancer lineages Daniel McGrail, PhD – The University of Texas MD Anderson Cancer Center
1:39 p.m.	Question & Answer Jiao Wang, PhD – Purdue University Ardiana Moustaki, PhD – St. Jude Children's Research Hospital Daniel McGrail, PhD – The University of Texas MD Anderson Cancer Center
Concurrent Rapid Oral Abstract Presentations - Clinical
Time: Location: Co-Chairs:	12:45 – 1:45 p.m. Cherry Blossom Ballroom Lorenzo Falchi, MD – Memorial Sloan Kettering Cancer Center Helen K. Angell, PhD – AstraZeneca
12:45 p.m.	(O68) Characteristics of the microbiome form and function of complete responders to Anti-PD1 and healthy individuals implicate donor selection for clinical trial design Md Abdul Wadud Khan, PhD – The University of Texas MD Anderson Cancer Center
12:53 p.m.	(O12) B-cells activated by checkpoint blockade immunotherapy and radiation improve overall survival in squamous cell carcinomas Sangwoo Kim, BA – University of California, San Diego
1:01 p.m.	(O77) Clinicopathological and genomic correlates of PD-L1 expression in nonsquamous non-small cell lung cancer Giuseppe Lamberti, MD – Dana-Farber Cancer Institute
1:09 p.m.	Question & Answer Md Abdul Wadud Khan, PhD – The University of Texas MD Anderson Cancer Center Sangwoo Kim, BA – University of California, San Diego Giuseppe Lamberti, MD – Dana-Farber Cancer Institute
1:15 p.m.	(O67) Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guérin (BCG) immunotherapy in early stage urothelial bladder cancer Randy F. Sweis, MD – University of Chicago
1:23 p.m.	Analysis of H&E Images Using Deep Learning for the Prediction of Distant Metastic Recurrence in Early Stage Melanoma Yvonne Saenger, MD – Columbia University Medical Center
1:31 p.m.	(O46) Characterization of tumor infiltrating and post HSCT NK and T cells in human cancer patients Sean Judge, MD, MS – University of California, Davis
1:39 p.m.	Question & Answer Randy F. Sweis, MD – University of Chicago Sean Judge, MD, MS – University of California, Davis
Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time: Location: Co-Chairs:	2:00 – 4:20 p.m. Potomac Ballroom Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute
2:00 p.m.	Introduction
2:05 p.m.	Targeting CD38 to optimize PD-1/PD-L1 and CTLA-4 Blockade Immunotherapy Don L. Gibbons, MD, PhD – The University of Texas MD Anderson Cancer Center
2:25 p.m.	Combinations: IL-2 Michael Hurwitz, MD, PhD – University of Texas MD Anderson Cancer Center
2:45 p.m.	The Emerging Role of TLR Agonists in Cancer Immunotherapy Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute
3:05 p.m.	Novel Targets: TIM-3 Hassane M. Zarour, MD – UPMC Hillman Cancer Center
3:25 p.m.	Immune Contexture and Immune Escape at Pre-Cancer Lesion Stages Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris
3:45 p.m.	(O40) Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers Jason Luke, MD, FACP – University of Pittsburgh Medical Center
4:00 p.m.	Panel Discussion Moderators: Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute Panelists: Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris Don L. Gibbons, MD, PhD – The University of Texas MD Anderson Cancer Center Jason Luke, MD, FACP – University of Pittsburgh Medical Center Hassane M. Zarour, MD – UPMC Hillman Cancer Center
4:15 p.m.	Closing
Concurrent Session 205: Biology of T cells
Time: Location: Co-Chairs	4:50 – 6:15 p.m. Potomac Ballroom CD Rafi Ahmed, PhD – Emory University Ana Carrizosa Anderson, PhD – Harvard Medical School
4:50 p.m.	InTOXication Causes T-cell Exhaustion in Chronic Infection Dietmar Zehn, PhD, MD – Technical University of Munich
5:15 p.m.	Single Cell Profiling of Anti-Tumor T cell Response Enrico Lugli, PhD – Instituto Clinico Humanitas IRCCS
5:40 p.m.	Molecular Networks in Tumour-Infiltrating T cells Anjana Rao, PhD – La Jolla Institute for Immunology
6:05 p.m.	(O49) Chronic activation under hypoxia drives T cell differentiation to exhaustion Nicole E. Scharping, PhD – University of Pittsburgh
Concurrent Session 206: High Impact Clinical Trials
Time: Location: Co-Chairs:	4:50 – 6:15 p.m. Prince George's Exhibition Hall C Jeffrey Weber, MD, PhD – NYU Langone Medical Center Roy Herbst, MD, PhD – Yale Cancer Center
4:50 p.m.	Introduction Roy Herbst, MD, PhD – Yale Cancer Center
4:55 p.m.	(O29) Phase I study of multisite stereotactic body radiotherapy plus nivolumab and urelumab or nivolumab and cabiralizumab in patients with advanced solid tumors Corey C. Foster, MD, MS – The University of Chicago Medicine
5:10 p.m.	(O26) A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis Matthew G. Krebs, MD, PhD –The University of Manchester
5:25 p.m.	(O27) Clinical response to tumor infiltrating lymphocytes (TIL) in stage 4 non-small cell lung cancer (NSCLC) correlates with neoantigen-specificity: A phase I trial Chao Wang, PhD – Moffitt Cancer Center
5:40 p.m.	(O18) Neoantigen vaccination targeting shared epidermal growth factor receptor (EGFR) mutations induces clinical and immunological responses in non-small cell lung cancer patients Gregory A. Lizee, PhD – The University of Texas MD Anderson Cancer Center
5:55 p.m.	(O21) Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs) Arun Rajan, MD – National Cancer Institute
6:10 p.m.	Closing Jeffrey Weber, MD, PhD – NYU Langone Medical Center
Concurrent Session 207: Harnessing Antigen-Presenting cells to Boost Anti-Tumor Immunity
Time: Location: Co-Chairs:	4:50 – 6:15 p.m. Potomac Ballroom AB Matthew Krummel, PhD – University of California, San Francisco Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT
4:50 p.m.	Tumor-Resident DC Impact Anti-Tumor T cell Responses Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT
5:10 p.m.	Phagocytic cells, Migratory cells, and Human Studies Matthew Krummel, PhD – University of California, San Francisco
5:30 p.m.	Basic Biology of Regulation of the cell Biology of Antigen Cross-Presentation by Dendritic cells Julie Magarian Blander, PhD – Weill Cornell Medicine
5:50 p.m.	(O44) Intratumoral CD163+ DC amplify the type 1 immune response of CD4+CD161+ T cells in HPV16-associated cancers and are associated with better survival Chantal Duurland, PhD – Leiden University Medical Center
6:00 p.m.	(O57) Novel dsRNA-sensing dendritic cells enhance anti-tumor immunity Ellen Duong, ScB – MIT
6:10 p.m.	Abstract Question and Answer Chantal Duurland, PhD – Leiden University Medical Center Ellen Duong, ScB – MIT
Concurrent Session 208: Tumor Cell Atlas Efforts – Big Data
Time: Location: Chair:	4:50 – 6:15 p.m. Cherry Blossom Ballroom Orit Rozenblatt-Rosen, PhD – Broad Institute
4:50 p.m.	Inflammatory Microenvironment in Breast Cancer Brain Metastasis Devon A. Lawson, PhD – University of California, Irvine
5:10 p.m.	Glioma Mario Suva, MD, PhD – Harvard Medical School, Massachusetts General Hospital
5:30 p.m.	Highplex Profiling of Microsatellite Stable and Instable Human Colorectal Carcinoma Karin Pelka, PhD – Broad Institute of MIT and Harvard
5:50 p.m.	(O80) Atlas of clinically-distinct cell states and cellular ecosystems across human solid tumors Andrew Gentles, PhD – Stanford University
6:00 p.m.	(O42) Transcriptional dissection reveals antitumor role of T follicular helper cells in head and neck cancer Anthony R. Cillo, PhD – University of Pittsburgh
6:10 p.m.	Question & Answer Andrew Gentles, PhD – Stanford University Anthony R. Cillo, PhD – University of Pittsburgh
Concurrent Session 209: Virus Driven Cancers
Time: Location: Co-Chairs:	4:50 – 6:15 p.m. National Harbor 10-11 Robert Ferris, MD, PhD – UPMC Hillman Cancer Center Weijing Sun, MD, FACP – University of Kansas Medical Center
4:50 p.m.	HPV and Head and Neck Cancers Robert Ferris, MD, PhD – UPMC Hillman Cancer Center
5:05 p.m.	EBV and Cancers Cliona M. Rooney, PhD – Baylor College of Medicine
5:20 p.m.	Evolving Role of HCV in Liver Cancer Jody C. Olson, MD, FACP – University of Kansas Medical Center
5:35 p.m.	Merkel Cell Carcinoma: Viral Antigens as Tumor Rejection Antigens Suzanne L. Topalian, MD – Johns Hopkins University School of Medicine
5:50 p.m.	(O19) Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC) Shailender Bhatia, MD – University of Washington
6:00 p.m.	(O17) A novel enantio-specific cationic lipid R-DOTAP + HPV16 E6 & E7 antigens induces potent antigen-specific CD8+ T cell responses in-vivo in subjects with CIN and high-risk human papillomavirus infection Lauren V. Wood, MD – PDS Biotechnology
6:10 p.m.	Question & Answer Shailender Bhatia, MD – University of Washington Lauren V. Wood, MD – PDS Biotechnology
Poster Reception
Time: Location:	6:30 – 8:00 p.m. Prince George's Exhibition Halls AB
Sponsored Symposia
Time: Location:	6:30 - 8:00 p.m. Riverview Ballroom B 4-5
6:30 p.m.	High-Plex Spatial Analysis of the Tumor Microenvironment: Advancements and Applications Akoya Biosciences, Inc.
Career Connections Networking Reception
Time: Location:	8:15 – 9:30 p.m. Potomac Ballroom Foyer

Saturday, Nov. 9, 2019

Point-Counterpoint: New Data and Controversies on Immunotherapy Combinations in the First-Line Treatment of NSCLC

Time:
Location:

7:00 - 7:45 a.m.
Cherry Blossom Ballroom

7:00 a.m.

Single Agents
Naiyer A. Rizvi, MD – Columbia University Medical Center

7:10 a.m.

IO-IO Combinations
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

7:20 a.m.

IO-chemotherapy Combinations
Roy Herbst, MD, PhD – Yale Cancer Center

7:30 a.m.

Panel Discussion
Moderators:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Mario Sznol, MD – Yale Cancer Center

Panelists:
Naiyer A. Rizvi, MD – Columbia University Medical Center
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Roy Herbst, MD, PhD – Yale Cancer Center

7:50 a.m.

Organizer Welcome
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Session 300: SITC Initiatives Update

Time:
Location:

7:55 – 8:40 a.m.
Potomac Ballroom

7:55 a.m.

SITC Anti-PD-1/PD-L1 Resistance Taskforce Update
Ryan J. Sullivan, MD – Massachusetts General Hospital

8:10 a.m.

SITC Policy Committee Update
George J. Weiner, MD – University of Iowa

Session 301: Friends of Cancer Research Update

Time:
Location:

8:40 – 8:55 a.m.
Potomac Ballroom

8:40 a.m.

Project Update: Friends of Cancer Research TMB Harmonization Consortium
Jeff Allen, PhD - Friends of Cancer Research

Session 302: Keynote Address

Time:
Location:
Chair:

8:55 – 9:45 a.m.
Potomac Ballroom
Mario Sznol, MD – Yale School of Medicine

8:55 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9:00 a.m.

Using Advanced Multiplex Optical Imaging Methods to Study the Tumor Micro-environment and Response to Cancer Immunotherapy
Ronald N. Germain, MD, PhD – NIAID, NIH

9:40 a.m.

Question & Answer
Ronald N. Germain, MD, PhD – NIAID, NIH

Session 303: Imaging Technologies

Time:
Location:
Co-Chairs:

9:45 –11:50 a.m.
Potomac Ballroom
Carlo Bifulco, MD – Providence Portland Medical Center
Michael Dustin, PhD – The Kennedy Institute of Rheumatology

9:45 a.m.

Introduction
Carlo Bifulco, MD – Providence Portland Medical Center

9:50 a.m.

Super-Resolution Imaging
Michael Dustin, PhD – The Kennedy Institute of Rheumatology

10:05 a.m.

IO Neoadjuvant Response Assessment by mIHCm
Janis Taube, MD, MSc – Johns Hopkins Medicine

10:20 a.m.

Multiplexed Imaging of Tissues- MIBI or CODEX
Michael Angelo, MD, PhD – Stanford Medicine

10:35 a.m.

Break

10:50 a.m.

Integrating Single-cell RNA-Seq with Spatial Transcriptomics in Pancreatic Ductal Adenocarcinoma
Itai Yanai, PhD – NYU School of Medicine

11:05 a.m.

ImmunoPET for Whole Body Imaging of Immune Cell Subsets
Anna M. Wu, PhD – University of California, Los Angeles

11:20 a.m.

Real-Time Insights into the Innate Immune Reaction Against Early Stage Glioblastomas
Dorian McGavern, PhD – National Institutes of Health

11:35 a.m.

(O1) Flexible Copper-64-nanoparticle-based cell labeling system allows for in vivo tracking of adoptively transferred T-cells by PET/CT
Hólmfridur R. Halldórsdóttir, MSc – Technical University of Denmark

Session 304: Late-Breaking Abstract Session

Time:
Location:
Chair:

11:50 a.m. – 12:20 p.m.
Potomac Ballroom
Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and
Research Institute

11:50 a.m.

(O82) A phase 1 dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
Geoffrey Ku, MD – Memorial Sloan Kettering Cancer Center

12:05 p.m.

(O81) IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC
Giuseppe Giaccone, MD, PhD – Weil Cornell Medicine

Session 305: SITC Sparkathon 2018 (SITCure): When is it Safe to Stop Immunotherapy? A Randomized Trial of Early Cessation of Immunotherapy in Patients with Melanoma after 6 Months or More of Stable Disease on Nivolumab Maintenance

Time:
Location:

12:20 – 12:35 p.m.
Potomac Ballroom

12:20 p.m.

SITC Sparkathon 2018 (SITCure): When is it Safe to Stop Immunotherapy? A Randomized Trial of Early Cessation of Immunotherapy in Patients with Melanoma after 6 Months or More of Stable Disease on Nivolumab Maintenance
Thomas Marron, MD, PhD – Mount Sinai Hospital

Lunch, Exhibits, and Poster Viewing

Time:
Location:

12:50 – 1:50 p.m.
Prince George's Exhibition Halls AB
Even Numbered Posters Presented

Concurrent Rapid Oral Abstract Presentations - Basic Research

Time:
Location:
Co-Chairs:

12:50 – 1:50 p.m.
National Harbor 10-11
Jessica E. Thaxton, PhD – Medical University of South Carolina
Aaron Ring, MD, PhD – Yale School of Medicine

12:50 p.m.

(O69) Helicobacter hepaticus remodels the tumor immune microenvironment and reduces colorectal tumor burden
Abigail E. Overacre-Delgoffe, PhD - University of Pittsburgh

12:58 p.m.

(O75) Selective induction of S100a8/a9 heterodimer protein in pancreatic cancer in response to immune selection pressure

Reham Ajina, MS- Georgetown University

1:06 p.m.

(O47) IL-35+ B cells regulates anti-tumor immune response in pancreatic cancer
Bhalchandra Mirlekar, PhD - University of North Carolina at Chapel Hill

1:14 p.m.

Question & Answer
Abigail E. Overacre-Delgoffe, PhD - University of Pittsburgh
Reham Ajina, MS- Georgetown University
Bhalchandra Mirlekar, PhD - University of North Carolina at Chapel Hill

1:20 p.m.

(O41) Vasoactive intestinal peptide: a novel checkpoint pathway in pancreatic ductal adenocarcinoma
Sruthi Ravindranathan, PhD - Emory University

1:28 p.m.

(O48) Characterizing the anti-tumor immune response to an array of tumor cell lines expressing unique neoantigens
Kim B. Nguyen, BA - Massachusetts Institute of Technology

1:36 p.m.

Tumor-infiltrating regulatory T cell function is metabolically supported through lactate-mediated symbiosis with the tumor microenvironment
McLane Watson, BS – University of Pittsburgh

1:14 p.m.

Question & Answer
Sruthi Ravindranathan, PhD - Emory University
Kim B. Nguyen, BA - Massachusetts Institute of Technology
Maria Cortez, PhD - The University of Texas MD Anderson Cancer

Concurrent Rapid Oral Abstract Presentations - Clinical

Time:
Location:
Co-Chairs:

12:50 – 1:50 p.m.
Cherry Blossom Ballroom
Grey Wilkinson, PhD – Oncolytics Biotech Inc.
Aung Naing, MD – MD Anderson Cancer Center

12:50 p.m.

(O78) Identification of breast cancer neoantigens exposed by radiation therapy
Claire Lhuillier, PhD – Weill Cornell Medical College

12:58 p.m.

(O33) Immune enrichment and functional T-cell receptor (TCR) frequencies predict response to immune checkpoint blockade (ICB) in selected fusion-associated sarcomas
Akash Mitra, BS – The University of Texas MD Anderson Cancer Center

1:06 p.m.

(O10) Licensing of CAR-T cell persistence and function by STING agonist in breast cancer
Nuo Xu, PhD Candidate – University of North Carolina at Chapel Hill

1:14 p.m.

Question & Answer
Claire Lhuillier, PhD – Weill Cornell Medical College
Akash Mitra, BS – The University of Texas MD Anderson Cancer Center
Nuo Xu, PhD Candidate – University of North Carolina at Chapel Hill

1:20 p.m.

(O2) Combining transcriptomic and tissue-based immune biomarkers to improve recurrence prediction in stage II-III melanoma
Robyn Gartrell, MD – Columbia University/ New York Presbyterian

1:28 p.m.

(O70) CD122-selective IL-2 complexes treat ovarian carcinomas, possibly by dysregulating Treg differentiation and reducing suppression, and promoting T cell stem cells
Yilun Deng, MD, PhD – UT Health San Antonio

1:36 p.m.

(O73) Designed improvement to T-cell immunotherapy by integrated single cell profiling
Irfan N. Bandey, PhD – University of Houston

1:14 p.m.

Question & Answer
Robyn Gartrell, MD – Columbia University/ New York Presbyterian
Yilun Deng, MD, PhD – UT Health San Antonio
Irfan N. Bandey, PhD – University of Houston

Sponsored Symposia

Time:
Location:

12:35 – 1:35 p.m.
Riverview Ballroom B 4-5

12:35 p.m.

Adaptive Biotechnologies’ Immune Medicine Platform — Aiming to transform the diagnosis and treatment of disease
Adaptive Biotechnologies

Time:
Location:

12:35 – 1:35 p.m.
Riverview Ballroom A3

12:35 p.m.

Immune Profiling of Clinical Cohort Samples Using Highly Multiplexed Ion Beam Imaging (MIBI) Technology to Characterize Spatial Organization in the Tumor Microenvironment
IONpath, Inc.

Session 306: Presidential Session

Time:
Location:
Chair:

2:05 – 3:30 p.m.
Potomac Ballroom
Mario Sznol, MD – Yale School of Medicine

2:05 p.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

2:10 p.m.

(O45) Overexpression of CD200 is a stem cell-specific mechanism of T cell evasion in AML
Shelley Herbrich, MS – The University of Texas MD Anderson Cancer Center

2:25 p.m.

(O56) Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells
Erik Wennerberg, PhD – Weill Cornell Medicine

2:40 p.m.

Expert Discussant
Dario A.A. Vignali, PhD – University of Pittsburgh

2:50 p.m.

(O66) Patient-derived microbiota germ-free mouse model for identifying mechanisms of checkpoint blockade efficacy modulation
Vyara Matson, PhD – University of Chicago

3:05 p.m.

(O8) The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment
Elizabeth R. Stirling – Wake Forest University

3:20 p.m.

Expert Discussant

Madhav V. Dhodapkar, MD – Emory University

Concurrent Session 307: Machine Learning Approaches and Applications

Time:
Location:
Co-Chairs:

3:45 – 5:00 p.m.
Cherry Blossom Ballroom
Douglas Lauffenburger, PhD – Massachusetts Institute of Technology
Kurt A. Schalper, MD, PhD – Yale School of Medicine

4:15 p.m.

An Introduction to Machine Learning Approaches for Immune System Applications
Douglas Lauffenburger, PhD – Massachusetts Institute of Technology

3:45 p.m.

Clinicopathologic and Molecular Markers to Assess Anti-tumor Immune Responses
Kurt A. Schalper, MD, PhD – Yale School of Medicine

4:00 p.m.

Deciphering Cell-Cell Interactions in the Melanoma TME from Single-cell Profiling Data
Kathryn Miller-Jensen, PhD – Yale University

4:30 p.m.

Enhancing Predictors of Neoantigens and TCRs
Marta Łuksza, PhD – Mount Sinai

4:45 p.m.

(O65) Artificial intelligence-powered retrospective analysis of PD-L1 expression in nivolumab trials of advanced non-small cell lung cancer
Vipul Baxi, MS – Bristol-Myers Squibb

Concurrent Session 308: Clinical Management

Time:
Location:
Co-Chairs:

3:45 – 5:00 p.m.
National Harbor 10-11
Marianne Davies, DNP, AOCNP – Yale School of Nursing
Elad Sharon, MD, MPH – National Cancer Institute

3:45 p.m.

Response Criteria/ Patient Selection
Nicole Drezner, MD – Food & Drug Administration

4:05 p.m.

Management of Complex IO Toxicity
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

4:25 p.m.

Severe Immunotherapy Complications (SIC) Service: A Model Integrating Clinical Care and Translational Research
Kerry Reynolds, MD – Massachussets General Hospital

4:45 p.m

(O64) Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease
Hamzah Abu-Sbeih, MD – The University of Texas MD Anderson Cancer Center

Concurrent Session 309: Single Agent Phase 1 Clinical Trials

Time:
Location:
Co Chairs:

3:45 – 5:00 p.m.
Prince George's Exhibition Hall C
Helen Chen, MD – National Cancer Institute
Naiyer Rizvi, MD – Columbia University Medical Center

3:45 p.m.

(O31) Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types
Jacob Thomas, MD – USC Norris Comprehensive Cancer Center

4:00 p.m.

(O30) A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors
Ben Markman, MBBS FRACP – Monash Medical Centre, Monash Health

4:15 p.m.

(O32) Single agent anti-tumor activity in PD-1 refractory NSCLC: phase 1 data from the first-in-human trial of NC318, a Siglec-15-targeted antibody
Anthony W. Tolcher, MD, FRCPC – Next Oncology

4:30 p.m.

(O36) A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors
Ulrike Gnad-Vogt, MD – CureVac AG

4:45 p.m.

(O28) First-in-Class Small Molecule CA-170 Targeting VISTA: A Report on Efficacy Outcomes from a Cohort of 12 Malignant Pleural Mesothelioma (MPM) Patients in Study CA-170-101
Marjorie G. Zauderer, MD, MS, FACP – Memorial Sloan Kettering Cancer Center

Break

Concurrent Session 310: Combination Phase 1-2 Clinical Trials
Time: Location: Co-Chairs:	5:15 – 6:30 p.m. Prince George's Exhibition Hall C Adil Daud, MBBS, MD – University of California, San Francisco Howard Streicher, MD – National Cancer Institute
5:15 p.m.	(O35) Clinical activity of BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: updated results from the phase 1/2 PIVOT-02 study Adi Diab, MD – The University of Texas MD Anderson Cancer Center
5:30 p.m.	(O20) A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma Alexander N. Shoushtari, MD – Memorial Sloan Kettering Cancer Center
5:45 p.m.	(O24) Phase II trial of concurrent nivolumab and radiation therapy in chemotherapy ineligible muscle invasive bladder cancer [NUTRA trial NCT03421652] Ulka N. Vaishampayan, MD – Wayne State University and Barbara Ann Karmanos Cancer Institute
6:00 p.m.	(O16) Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) Alexander Stein, MD – University Cancer Center Hamburg
6:15 p.m.	(O23) Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI) Pavlos Msaouel, MD, PhD – The University of Texas MD Anderson Cancer Center
Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors
Time: Location: Co-Chairs:	5:15 – 6:30 p.m. National Harbor 10-11 Hideho Okada, MD, PhD – University of California, San Francisco David Reardon, MD – Dana-Farber Cancer Institute
5:15 p.m.	Neoadjuvant Immunotherapy for Glioblastoma Robert Prins, PhD – University of California, Los Angeles
5:35 p.m.	Immunotherapy for CNS Metastatic Tumors Harriet M. Kluger, MD – Yale School of Medicine
5:55 p.m.	Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors Richard M. Sherry, MD – National Institutes of Health
6:15 p.m.	(O22) Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastoma Daniela Bota, MD, PhD – University of California Irvine
Concurrent Session 312: NK Cells: From Basic Science to Clinical Application
Time: Location: Co-Chairs:	5:15 – 6:30 p.m. Potomac Ballroom AB Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai David Raulet, PhD – University of California, Berkeley
5:15 p.m.	Harnessing Innate Immunity in Cancer Eric Vivier, DVM, PhD – Aix Marseille University, Publique de Hôptiaux de Marseille, Innate-Pharma
5:35 p.m.	Natural Killer cells are Susceptible to Effector cell Dysfunction in Human Bladder Cancer Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
5:55 p.m.	Mobilization of Natural Killer Cells for Immunotherapy of Cancer David Raulet, PhD – University of California, Berkeley
6:15 p.m.	(O6) Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape Yimin Du, PhD – Salk Institute for Biological Studies
Concurrent Session 313: Immunotherapy Advances in Skin Cancer
Time: Location: Co-Chairs:	5:15 – 6:30 p.m. Cherry Blossom Ballroom Shailender Bhatia, MD – University of Washington Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'
5:15 p.m.	Immunotherapy Advances in Non-Melanoma Skin Cancer Shailender Bhatia, MD – University of Washington
5:35 p.m.	Advances in Melanoma Adjuvant Therapy: Implications for Clinical Practice and Future Research Ahmad A. Tarhini, MD, PhD – Moffitt Comprehensive Cancer Center and Research Institute
5:55 p.m.	Immunotherapy Advances in Melanoma Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'
6:15 p.m.	(O34) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High Risk Resectable Melanoma (MEL): Preliminary Results Diwakar Davar, MD – UPMC Hillman Cancer Center
Concurrent Session 314: Tumor and Stromal Cell Biology
Time: Location: Co-Chairs:	5:15 – 6:30 p.m. Potomac Ballroom CD Kwok-Kin Wong, MD, PhD – New York Langone Health Neta Erez, PhD – Tel Aviv University
5:15 p.m.	In the Wnt-er of Life: How Wnt Signaling in the Tumor Microevironment Drives Age-Related Tumor Progression Ashani Weeraratna, PhD – The Wistar Institute
5:35 p.m.	Tumor Microenvironment Rosandra Kaplan, MD – National Institutes of Health, National Cancer Institute
5:55 p.m.	Pancreatic Cancer David Tuveson, MD, PhD – Cold Spring Harbor Laboratory
6:15 p.m.	(O74) Fibroblast activation protein is expressed by human and murine leukocytes and nonspecific inhibition of FAP enhances anti-PD-1 therapy in murine models of PDAC Allison Fitzgerald, MD/PhD Candidate – Georgetown University
Award Ceremony
Time: Location:	6:30 – 7:00 p.m. Prince George's Exhibition Hall C
Poster Reception
Time: Location:	7:00 – 8:30 p.m. Prince George's Exhibition Hall AB
The Checkpoints Band Party
Time: Location:	8:30 – 11:30 p.m. Riverview Ballroom
Sunday, Nov. 10, 2019
8:00 a.m.	Organizer Welcome Marianne Davies, DNP, AOCNP – Yale School of Nursing
Session 400: Innovations in Cellular Therapy for Therapeutically Targeting Advanced Malignancies
Time: Location: Co-Chairs:	8:05 – 10:15 a.m. Prince George's Exhibition Hall C Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center Ingunn Stromnes, PhD – University of Minnesota
8:05 a.m.	Targeting Neoantigens Christopher A. Klebanoff, MD – Memorial Sloan Kettering Cancer Center
8:25 a.m.	Dual Targeting CAR T cell Crystal Mackall, MD – Stanford University
8:45 a.m.	Early Stage Cellular Therapy Trials Katyoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center
9:05 a.m.	Gene Editing Avery D. Posey, Jr., PhD – University of Pennsylvania
9:25 a.m.	NK Cell Therapy: Individual Donor Products to Off-the-Shelf Multi-Dosing Strategies Jeffrey S. Miller, MD – University of Minnesota
9:45 a.m.	(O51) Sirt2 inhibition enhances anti-tumor immunity by promoting T cell metabolism Imene Hamaidi, PhD – Moffit Cancer Center
10:00 a.m.	(O5) The road-map to Tumor-Infiltrating Lymphocyte (TIL) therapy: Understanding genetic alterations for improved patient treatment Caitlin Creasy – MD Anderson Cancer Center, UTHealth GSBS
Session 401: Update Session
Time: Location:	10:30 – 11:00 a.m. Prince George's Exhibition Hall C
10:30 a.m.	Food and Drug Administration Update Marc Theoret, MD – U.S. Food and Drug Administration, OHOP
Session 402: Hot Topic Symposium: Modifiable Host Factors and Immune Response
Time: Location: Co-Chairs:	11:00 a.m. – 12:30 p.m. Prince George's Exhibition Hall C Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute Jennifer McQuade, MD, MS, MA, LAc – The University of Texas MD Anderson Cancer Center
11:00 a.m.	Introduction Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute
11:10 a.m.	Fiber/Microbiome Jennifer McQuade, MD, MS, MA, LAc – The University of Texas MD Anderson Cancer Center
11:30 a.m.	Obesity William J. Murphy, PhD – University of California, Davis
11:50 a.m.	Exercise Connie J. Rogers, PhD, MPH – The Pennsylvania State University
12:10 p.m.	Panel Discussion
	Moderator: Jennifer A. Ligibel, MD – Dana-Farber Cancer Institute
	Panelists: Jennifer McQuade, MD, MS, MA, LAc – The University of Texas MD Anderson Cancer Center William J. Murphy, PhD – University of California, Davis Connie J. Rogers, PhD, MPH – The Pennsylvania State University